Comparison · NCT01962870-bd3f63ad
Vasopressin vs Placebo: Change From Baseline on the Overt Aggression Scale (OAS) During Treatment.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vasopressin vs Placebo: Change From Baseline on the Overt Aggression Scale (OAS) During Treatment. Trial comparisons, record NCT01962870-bd3f63ad. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01962870-bd3f63ad
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0588 | 0.0105 | 0.27 | wilson | |
| Risk in group 2 | 0.0769 | 0.0137 | 0.333 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0181 | -0.279 | 0.202 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.765 | 0.0526 | 11.1 | log | |
| Odds ratio, group 1 over group 2 | 0.75 | 0.0425 | 13.2 | log | |
| Number needed to treat, for one fewer participant with the outcome on Vasopressin than on Placebo | 55.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vasopressin | Vasopressin Nasal Spray~Vasopressin: Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily). | 1 | 17 | OG001 |
| Group 2 | Placebo | Placebo Nasal Spray~Placebo | 1 | 13 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Change From Baseline on the Overt Aggression Scale (OAS) During Treatment.
- Description
- Count of participants reporting an increase of aggression during treatment compared to baseline (pretreatment).
- Time frame
- Baseline through Week 4
- Population
- Participants with available data are included in the analysis.
Source ClinicalTrials.gov
Trial
- Title
- The Role of Vasopressin in the Social Deficits of Autism
- NCT number
- NCT01962870
- Phases
- PHASE2
- Conditions
- Autism Spectrum Disorders
- Interventions
- Vasopressin, Placebo
- Lead sponsor
- Stanford University
- Results first posted
- 2019-05-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01962870?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01962870-bd3f63ad